title: Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
authors.forename: Takanori
authors.initials: T
authors.lastname: Hidaka
authors.forename: Taku
authors.initials: T
authors.lastname: Fujimura
authors.forename: Akiko
authors.initials: A
authors.lastname: Watabe
authors.forename: Akira
authors.initials: A
authors.lastname: Hashimoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Haga
authors.forename: Kaoru
authors.initials: K
authors.lastname: Onami
authors.forename: Masato
authors.initials: M
authors.lastname: Mizuashi
authors.forename: Setsuya
authors.initials: S
authors.lastname: Aiba
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D000069287:Capecitabine; D002277:Carcinoma / Q000737:chemistry / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006258:Head and Neck Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D000077341:Lapatinib; D008113:Liver Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012535:Scalp / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D012878:Skin Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D000069287:Capecitabine; D003841:Deoxycytidine; D005472:Fluorouracil; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human